by Melanie Senior
When UCB Group announced its acquisition of Celltech Group PLC in May 2004, some UK industry observers frowned: yet...
Chroma: Next Generation UK Biotech
Recent M&A activity may have led to fewer top ranking UK biotech firms, but far from weakening the sector, it's actually providing opportunities for a newer generation of companies. Chroma Therapeutics Ltd. provides a good illustration of how experienced UK management talent is moving to lead younger, often private firms.
More from Strategy
More from Business
• By
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
• By
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
• By
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.